1. Neuroinflammatory disease disrupts the blood-CNS barrier via crosstalk between proinflammatory and endothelial-to-mesenchymal-transition signaling
- Author
-
Zhonglou Sun, Helong Zhao, Daniel Fang, Chadwick T. Davis, Dallas S. Shi, Kachon Lei, Bianca E. Rich, Jacob M. Winter, Li Guo, Lise K. Sorensen, Robert J. Pryor, Nina Zhu, Samuel Lu, Laura L. Dickey, Daniel J. Doty, Zongzhong Tong, Kirk R. Thomas, Alan L. Mueller, Allie H. Grossmann, Baowei Zhang, Thomas E. Lane, Robert S. Fujinami, Shannon J. Odelberg, and Weiquan Zhu
- Subjects
Central Nervous System ,Mice, Inbred C57BL ,Mice ,Encephalomyelitis, Autoimmune, Experimental ,Multiple Sclerosis ,Activin Receptors ,General Neuroscience ,Neuroinflammatory Diseases ,Animals ,Receptor Protein-Tyrosine Kinases ,Monomeric GTP-Binding Proteins ,Signal Transduction - Abstract
Breakdown of the blood-central nervous system barrier (BCNSB) is a hallmark of many neuroinflammatory disorders, such as multiple sclerosis (MS). Using a mouse model of MS, experimental autoimmune encephalomyelitis (EAE), we show that endothelial-to-mesenchymal transition (EndoMT) occurs in the CNS before the onset of clinical symptoms and plays a major role in the breakdown of BCNSB function. EndoMT can be induced by an IL-1β-stimulated signaling pathway in which activation of the small GTPase ADP ribosylation factor 6 (ARF6) leads to crosstalk with the activin receptor-like kinase (ALK)-SMAD1/5 pathway. Inhibiting the activation of ARF6 both prevents and reverses EndoMT, stabilizes BCNSB function, reduces demyelination, and attenuates symptoms even after the establishment of severe EAE, without immunocompromising the host. Pan-inhibition of ALKs also reduces disease severity in the EAE model. Therefore, multiple components of the IL-1β-ARF6-ALK-SMAD1/5 pathway could be targeted for the treatment of a variety of neuroinflammatory disorders.
- Published
- 2022
- Full Text
- View/download PDF